PRAH Key Statistics, Chart & Performance
The current stock price of PRAH is 165.21 null. In the past month the price decreased by -2.76%. In the past year, price increased by 73.81%.
PRAH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.93 | 218.19B | ||
| DHR | DANAHER CORP | 29.87 | 162.69B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 185.88 | 56.48B | ||
| A | AGILENT TECHNOLOGIES INC | 24.8 | 39.23B | ||
| IQV | IQVIA HOLDINGS INC | 19.51 | 38.64B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 33.94 | 29.01B | ||
| WAT | WATERS CORP | 30.4 | 22.98B | ||
| ILMN | ILLUMINA INC | 30.95 | 20.62B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.8 | 19.73B | ||
| MEDP | MEDPACE HOLDINGS INC | 39.69 | 15.99B | ||
| TEM | TEMPUS AI INC | N/A | 11.15B | ||
| RVTY | REVVITY INC | 20.2 | 10.97B |
Related stock screener links
About PRAH
Company Profile
PRA Health Sciences, Inc. engages in the provision of outsourced clinical development services to the biotechnology and pharmaceutical industries. The company is headquartered in Raleigh, North Carolina and currently employs 18,100 full-time employees. The company went IPO on 2014-11-13. The firm provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The firm offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. Its services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. The company provides its clients with clinical development service offerings, which includes both traditional, project-based Phase I through Phase IV services, as well as embedded and functional outsourcing services. As of December 31, 2016, its clinical development platform included approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East. The firm's service offerings include product registration, strategic solutions and early development services.
Company Info
Pra Health
4130 Parklake Ave Ste 400
Raleigh NORTH CAROLINA 27612 US
CEO: Colin Shannon
Employees: 18100.0
Phone: 19197868200.0
Pra Health / PRAH FAQ
Can you describe the business of Pra Health?
PRA Health Sciences, Inc. engages in the provision of outsourced clinical development services to the biotechnology and pharmaceutical industries. The company is headquartered in Raleigh, North Carolina and currently employs 18,100 full-time employees. The company went IPO on 2014-11-13. The firm provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The firm offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. Its services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. The company provides its clients with clinical development service offerings, which includes both traditional, project-based Phase I through Phase IV services, as well as embedded and functional outsourcing services. As of December 31, 2016, its clinical development platform included approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East. The firm's service offerings include product registration, strategic solutions and early development services.
What is the stock price of Pra Health today?
The current stock price of PRAH is 165.21 null. The price decreased by -1.67% in the last trading session.
Does PRAH stock pay dividends?
PRAH does not pay a dividend.
How is the ChartMill rating for Pra Health?
PRAH has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for PRAH stock?
4 analysts have analysed PRAH and the average price target is 171.11 null. This implies a price increase of 3.57% is expected in the next year compared to the current price of 165.21.
What is the Price/Earnings (PE) ratio of Pra Health (PRAH)?
The PE ratio for Pra Health (PRAH) is 32.65. This is based on the reported non-GAAP earnings per share of 5.06 and the current share price of 165.21 null.
Is Pra Health (PRAH) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PRAH.
PRAH Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to PRAH. When comparing the yearly performance of all stocks, PRAH is one of the better performing stocks in the market, outperforming 77.96% of all stocks.
PRAH Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PRAH. PRAH has a medium profitability rating, but doesn't score so well on its financial health evaluation.
PRAH Financial Highlights
Over the last trailing twelve months PRAH reported a non-GAAP Earnings per Share(EPS) of 5.06. The EPS decreased by -1.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 6.4% | ||
| ROA | 4.98% | ||
| ROE | 13.71% | ||
| Debt/Equity | 0.74 |
PRAH Forecast & Estimates
4 analysts have analysed PRAH and the average price target is 171.11 null. This implies a price increase of 3.57% is expected in the next year compared to the current price of 165.21.
For the next year, analysts expect an EPS growth of 29.21% and a revenue growth 19.32% for PRAH